Targeted radioactive therapy for prostate cancer

Michael Hofman and colleagues1 report more frequent prostate-specific antigen response and prolonged progression-free survival with lutetium-177 [177Lu]Lu-PSMA-617, compared with cabazitaxel, in patients with metastatic castration-resistant prostate cancer with high prostate-specific membrane antigen (PSMA) expression. Nevertheless, the median progression-free survival was 5·1 months in both arms, but a subpopulation of 19% of patients had a 1-year progression-free survival with [177Lu]Lu-PSMA-617 versus 3% with cabazitaxel.